JP2005526778A5 - - Google Patents

Download PDF

Info

Publication number
JP2005526778A5
JP2005526778A5 JP2003576589A JP2003576589A JP2005526778A5 JP 2005526778 A5 JP2005526778 A5 JP 2005526778A5 JP 2003576589 A JP2003576589 A JP 2003576589A JP 2003576589 A JP2003576589 A JP 2003576589A JP 2005526778 A5 JP2005526778 A5 JP 2005526778A5
Authority
JP
Japan
Prior art keywords
antigen
composition
double
stranded rna
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003576589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005526778A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/007995 external-priority patent/WO2003078595A2/en
Publication of JP2005526778A publication Critical patent/JP2005526778A/ja
Publication of JP2005526778A5 publication Critical patent/JP2005526778A5/ja
Pending legal-status Critical Current

Links

JP2003576589A 2002-03-15 2003-03-14 免疫調節性非コードｒｎａモチーフを用いて抗体及び主要組織適合性クラスｉ拘束性又はクラスｉｉ拘束性ｔ細胞の応答を開始或いは増強させるための組成物及び方法 Pending JP2005526778A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36449002P 2002-03-15 2002-03-15
US41221902P 2002-09-20 2002-09-20
PCT/US2003/007995 WO2003078595A2 (en) 2002-03-15 2003-03-14 Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response

Publications (2)

Publication Number Publication Date
JP2005526778A JP2005526778A (ja) 2005-09-08
JP2005526778A5 true JP2005526778A5 (enExample) 2006-04-27

Family

ID=28045408

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003576589A Pending JP2005526778A (ja) 2002-03-15 2003-03-14 免疫調節性非コードｒｎａモチーフを用いて抗体及び主要組織適合性クラスｉ拘束性又はクラスｉｉ拘束性ｔ細胞の応答を開始或いは増強させるための組成物及び方法

Country Status (6)

Country Link
US (1) US20050222060A1 (enExample)
EP (1) EP1485403A4 (enExample)
JP (1) JP2005526778A (enExample)
AU (1) AU2003218181A1 (enExample)
CA (1) CA2479187A1 (enExample)
WO (1) WO2003078595A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258712A3 (en) * 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
CA2520181A1 (en) 2003-03-26 2004-10-14 Astral Inc. Selected rna motifs to include cell death and/or apoptosis
WO2008017473A2 (en) * 2006-08-08 2008-02-14 Gunther Hartmann Structure and use of 5' phosphate oligonucleotides
AU2008266910A1 (en) * 2007-06-18 2008-12-24 Hemispherx Biopharma, Inc. Early intervention of viral infections with immune activators
CA2708956C (en) 2007-12-18 2018-07-17 Athera Biotechnologies Ab Use of annexin a5 for the treatment of vascular disease
EP2281043B1 (en) 2008-04-25 2013-03-13 Innate Pharma Improved tlr3 agonist compositions
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
HRP20230443T1 (hr) * 2011-05-24 2023-09-15 BioNTech SE Individualizirana cjepiva protiv raka
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
EP3746088B1 (en) * 2018-02-02 2024-07-10 University of Washington Compositions and methods for inducing tripartite motif-containing protein 16 (trim16) signaling

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906092A (en) * 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
US5906980A (en) * 1987-07-17 1999-05-25 Hem Research Inc. Treatment of hepatitis with mismatched dsRNA
US5683986A (en) * 1987-08-12 1997-11-04 Hemispherx Biopharma Inc. Elaboration of host defense mediators into biological fluids by systemic dsRNA treatment
US5593973A (en) * 1987-09-04 1997-01-14 Hemispherx Biopharma Inc. Treatment of viral hepatitis with mismatched dsRNA
DE69023900T4 (de) * 1989-02-24 1996-10-02 The Regents Of The University Of California, Berkeley, Calif. Gentechnologisch veränderte immunglobuline.
US5612035A (en) * 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
ZA908037B (en) * 1989-10-11 1991-09-25 Hem Res Inc Protection from shock subsequent to injury by double-standed rnas
US5998366A (en) * 1990-09-21 1999-12-07 The Regents Of The University Of California Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5696109A (en) * 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5958457A (en) * 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
WO1995026204A1 (en) * 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
HU221385B1 (en) * 1994-07-13 2002-09-28 Chugai Pharmaceutical Co Ltd Reconstituted human antibody against human interleukin-8
ES2366201T3 (es) * 1994-07-15 2011-10-18 University Of Iowa Research Foundation Oligonucleótidos inmunmoduladores.
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5698679A (en) * 1994-09-19 1997-12-16 National Jewish Center For Immunology And Respiratory Medicine Product and process for targeting an immune response
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
GB9501079D0 (en) * 1995-01-19 1995-03-08 Bioinvent Int Ab Activation of T-cells
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2301575C (en) * 1997-05-20 2003-12-23 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
TW589189B (en) * 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
KR20000034847A (ko) * 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
CA2390031A1 (en) * 1999-11-02 2001-05-25 Chiron Corporation Double-stranded rna receptor (dsrna-r) and methods relating thereto
JP4304900B2 (ja) * 2000-05-25 2009-07-29 富士ゼロックス株式会社 画像形成方法
US20040052763A1 (en) * 2000-06-07 2004-03-18 Mond James J. Immunostimulatory RNA/DNA hybrid molecules

Similar Documents

Publication Publication Date Title
JP2005526778A5 (enExample)
NO20015073D0 (no) Vaksiner
Abou-Alfa et al. The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?
FI1897548T4 (fi) T-solujen säätely
WO2006050250A3 (en) Dose forms comprising vx-950 and their dosage regimen
NZ597915A (en) Combination therapy for treatment of immune disorders
DE502004005154D1 (de) Multipartikuläre arzneiform, enthaltend mucoadhaesiv formulierte peptid- oder protein-wirkstoffe, sowie ein verfahren zur herstellung der arzneiform
WO2006041866A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
IL276515B1 (en) PD–L1-specific antibodies and methods of using them
JP2007522094A5 (enExample)
JP2016040288A5 (enExample)
JP2002506648A5 (enExample)
JP2007524613A5 (enExample)
JP2012504602A5 (enExample)
JP2019532047A5 (enExample)
JP2020533302A5 (enExample)
JP2005511495A5 (enExample)
Soriano et al. Treatment of hepatitis delta and HIV infection
JP2013028611A5 (enExample)
DE60141297D1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
WO2003078595B1 (en) Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
AR065765A1 (es) Composicion de vacuna para el tratamiento de enfermedades infecciosas respiratorias
JP2004523538A5 (enExample)
Niu et al. Synergistic and additive effects of cimetidine and levamisole on cellular immune responses to hepatitis B virus DNA vaccine in mice
Kolb et al. Effective use of tocilizumab for the treatment of steroid‐refractory gastrointestinal acute graft versus host disease in a child with very high levels of serum interleukin‐6